

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE

In re: Rosuvastatin Calcium	:	MDL No. 08-1949-JJF
Patent Litigation,	:	
<hr/>		
AstraZeneca Pharmaceuticals	:	
LP, AstraZeneca UK Limited,	:	
IPR Pharmaceuticals Inc., and	:	
Shionogi Seiyaku Kabushiki	:	
Kaisha,	:	
Plaintiffs,	:	
v.	:	Civil Action No. 07-805-JJF
Mylan Pharmaceuticals Inc.,	:	
Defendant.	:	
<hr/>		
AstraZeneca Pharmaceuticals	:	
LP, AstraZeneca UK Limited,	:	
IPR Pharmaceuticals Inc., and	:	
Shionogi Seiyaku Kabushiki	:	
Kaisha,	:	
Plaintiffs,	:	
v.	:	Civil Action No. 07-806-JJF
Sun Pharmaceutical Industries	:	
Ltd.,	:	
Defendant.	:	
<hr/>		
AstraZeneca Pharmaceuticals	:	
LP, AstraZeneca UK Limited,	:	
IPR Pharmaceuticals Inc., and	:	
Shionogi Seiyaku Kabushiki	:	
Kaisha,	:	
Plaintiffs,	:	
v.	:	Civil Action No. 07-807-JJF
Sandoz Inc.,	:	
Defendant.	:	

---

AstraZeneca Pharmaceuticals  
LP, AstraZeneca UK Limited,  
IPR Pharmaceuticals Inc., and  
Shionogi Seiyaku Kabushiki  
Kaisha,

Plaintiffs,

v.

Par Pharmaceuticals Inc.,

Defendant.

---

Civil Action No. 07-808-JJF

---

AstraZeneca Pharmaceuticals  
LP, AstraZeneca UK Limited,  
IPR Pharmaceuticals Inc., and  
Shionogi Seiyaku Kabushiki  
Kaisha,

Plaintiffs,

v.

Apotex Inc. and Apotex Corp.,

Defendants.

---

Civil Action No. 07-809-JJF

---

AstraZeneca Pharmaceuticals  
LP, AstraZeneca UK Limited,  
IPR Pharmaceuticals Inc., and  
Shionogi Seiyaku Kabushiki  
Kaisha,

Plaintiffs,

v.

Aurobindo Pharma Ltd. and  
Aurobindo Pharma USA Inc.,

Defendants.

---

Civil Action No. 07-810-JJF

AstraZeneca Pharmaceuticals	:	
LP, AstraZeneca UK Limited,	:	
IPR Pharmaceuticals Inc., and	:	
Shionogi Seiyaku Kabushiki	:	
Kaisha,	:	
	:	
Plaintiffs,	:	
	:	
v.	:	Civil Action No. 07-811-JJF
	:	

Cobalt Pharmaceuticals Inc.	:	
and Cobalt Laboratories Inc.,	:	
	:	
Defendants.	:	

---

AstraZeneca Pharmaceuticals	:	
LP, AstraZeneca UK Limited,	:	
IPR Pharmaceuticals Inc., and	:	
Shionogi Seiyaku Kabushiki	:	
Kaisha,	:	
	:	
Plaintiffs,	:	
	:	
v.	:	Civil Action No. 08-359-JJF
	:	

Aurobindo Pharma Ltd. and	:	
Aurobindo Pharma USA Inc.,	:	
	:	
Defendants.	:	

---

AstraZeneca Pharmaceuticals	:	
LP, AstraZeneca UK Limited,	:	
IPR Pharmaceuticals Inc., and	:	
Shionogi Seiyaku Kabushiki	:	
Kaisha,	:	
	:	
Plaintiffs,	:	
	:	
v.	:	Civil Action No. 08-426-JJF
	:	

Teva Pharmaceuticals USA,	:	
	:	
Defendant.	:	

**MEMORANDUM ORDER**

Pending before the Court are three Objections to the Report  
And Recommendation Regarding Motions For Summary Judgment And To

Dismiss, And Order On Evidentiary Motions (D.I.<sup>1</sup> 389) issued by Magistrate Judge Stark in the above-captioned actions: (1) an Objection filed by Plaintiffs (D.I. 393), (2) an Objection filed by Aurobindo Pharma Ltd. ("Aurobindo India") (D.I. 392), and (3) an Objection filed by Aurobindo Pharma USA, Inc. ("Aurobindo USA") (D.I. 391). For the reasons discussed, the Court will overrule the Objections filed by Plaintiffs, Aurobindo India, and Aurobindo USA.

#### **I. STANDARD OF REVIEW**

When reviewing the decision of a magistrate judge on a dispositive matter, the Court conducts a de novo review. 28 U.S.C. § 636(b)(1)(B); Fed. R. Civ. P. 72(b)(3). A motion to dismiss and a motion for summary judgment are considered dispositive matters, and therefore, the findings and conclusions of the magistrate judge in connection with such motions are reviewed de novo. Id. The court may accept, reject, or modify the recommendations of the magistrate judge. The court may also receive further evidence or return the matter to the magistrate judge with instructions for proceeding. Id.

---

<sup>1</sup> Objections were only filed in Civil Action Nos. 07-809 and 07-810, and therefore, the Court adopts the Report and Recommendation as filed in all of the remaining civil actions in which it was filed. For ease of reference, the Court will refer to the Docket Item numbers used in the multi-district action, MDL. No. 08-1949.

## II. DISCUSSION

### A. Plaintiffs' Objection

Plaintiffs object to that portion of the Magistrate Judge's Report and Recommendation concluding that the Court lacks personal jurisdiction over Apotex, Inc. ("Apotex") and granting Apotex's request to transfer this action to the Southern District of Florida. Plaintiffs contend that their objection "raises an important legal issue of first impression: whether a generic drug manufacturer's voluntary and persistent activities in this District in pursuit of its litigation-based business model constitute 'doing business' or 'persistent conduct' under the Delaware long arm statute sufficient to establish general jurisdiction." (D.I. 393 at 1). Plaintiffs contend that, as part of its business model, Apotex instigates litigation in this District and has been sued in this District numerous times, often voluntarily submitting to the jurisdiction of this Court and asserting counterclaims against the various plaintiffs. Plaintiffs contend that ANDA litigation in Delaware is at the "core" of Apotex's business model, and because Apotex avails itself of the resources of this Court to advance its business, the exercise of general jurisdiction over Apotex is appropriate.

Both Apotex and Aurobindo India have filed responses to Plaintiffs' Objection contending that participation in prior litigation in Delaware is insufficient to establish the

"substantial and continuous activity" required for the exercise of general jurisdiction. Apotex points out that it had no control over where it was sued, and the exercise of personal jurisdiction over Apotex would not further the purposes of the Delaware long-arm statute. In addition, Apotex contends that the Court should modify the Magistrate Judge's Report and Recommendation to dismiss Apotex outright from this litigation, thereby requiring Plaintiffs to re-file this action in a proper forum.

Reviewing the Report and Recommendation of Magistrate Judge Stark de novo, the Court concludes that Magistrate Judge Stark did not err in concluding that the Court lacks personal jurisdiction over Apotex. As Magistrate Judge Stark pointed out, Apotex and Apotex Corp. are distinct corporations whose relationship is insufficient to support an agency theory. Further, the Court is not persuaded that Apotex's participation, primarily as a defendant, in litigation in this District is sufficient to support the exercise of general jurisdiction. In addition, the Court further concludes that Magistrate Judge Stark appropriately concluded that this action should be transferred to the Southern District of Florida. Accordingly, the Court fully adopts the rationale set forth by Magistrate Judge in his Report and Recommendation, and therefore, the Court will overrule Plaintiffs' Objection.

B. Aurobindo India's Objection

Aurobindo India objects to that portion of the Magistrate Judge's Report and Recommendation recommending the denial of Aurobindo India's motion for summary judgment and its related request that Aurobindo USA be dismissed. Aurobindo India contends that the Court lacks personal jurisdiction over it, and Magistrate Judge Stark erred in finding genuine issues of material fact regarding application of the agent or alter-ego theories of establishing personal jurisdiction based on the acts of Aurobindo India's wholly-owned subsidiary, Aurobindo USA. Aurobindo India contends that Aurobindo USA is not its agent in Delaware, because Aurobindo India lacks the requisite control over Aurobindo USA, and Aurobindo USA does not conduct business in Delaware.

In response, Plaintiffs contend that they have presented sufficient evidence to show that Aurobindo USA is Aurobindo India's agent in the United States, and that Aurobindo USA has sufficient contacts with Delaware to support the exercise of jurisdiction. Alternatively, Plaintiffs contend that they have presented sufficient evidence to show that Aurobindo India controls Aurobindo USA, to such a great extent that the two companies can be considered alter egos.

Reviewing the Report and Recommendation of Magistrate Judge Stark de novo, the Court concludes that Magistrate Judge Stark

did not err in concluding that genuine issues of material fact exist as to whether the Court has personal jurisdiction over Aurobindo India. Magistrate Judge Stark summarized the evidence succinctly in his report and recommendation, and the Court agrees with his conclusion that this evidence, at a minimum, gives rise to questions of material fact regarding the application of the agency and alter-ego theories and whether Aurobindo USA's conduct is sufficient to establish general jurisdiction. Accordingly, the Court fully adopts the rationale set forth by Magistrate Judge Stark in his Report and Recommendation and will overrule Aurobindo India's Objection.

C. Aurobindo USA's Objection

Aurobindo USA objects to that portion of Magistrate Judge Stark's Report and Recommendation recommending the denial of Aurobindo USA's Motion For Summary Judgment Of Noninfringement And No Subject Matter Jurisdiction. Aurobindo USA contends that it did not "submit" the ANDA giving rise to this litigation, and therefore, the elements of Section 271(e)(2) cannot be met as a matter of law. Thus, Aurobindo USA contends that it is entitled to a judgment of noninfringement as a matter of law, and/or dismissal based upon lack of subject matter jurisdiction under Section 271(e)(2).

In response, Plaintiffs contend that the Court already rejected Aurobindo USA's argument when it adopted Magistrate



Judge Stark's 2008 Report and Recommendation. Plaintiff further contends that genuine issues of material fact exists regarding whether Aurobindo USA intends to benefit directly if the ANDA is approved, and whether Aurobindo USA signed and sent the ANDA to the FDA.

As Plaintiffs note, Aurobindo USA raises the same arguments it makes here in its previously filed Motion To Dismiss. In his November 24, 2008 Report and Recommendation, Magistrate Judge Stark rejected Aurobindo USA's arguments and recommended denial of the Motion To Dismiss. The Court adopted the 2008 Report and Recommendation, but noted that its rulings did not apply to a properly filed motion for summary judgment, which the Magistrate Judge should consider in the first instance. Having considered such a motion, Magistrate Judge Stark concluded that the record contains evidence from which a reasonable fact finder could find that Aurobindo USA is a wholly owned subsidiary of a foreign ANDA applicant (Aurobindo India), that it signed the ANDA as the agent for Aurobindo India, and that it intends to benefit directly if the ANDA is approved. Judge Stark also concluded that genuine issues of material fact exist as to at least some of the aforementioned factors. The Court agrees with Judge Stark's conclusions and fully adopts the rationale set forth in his Report and Recommendation. Accordingly, the Court will overrule Aurobindo USA's Objection.

NOW THEREFORE, IT IS HEREBY ORDERED that:

1. Plaintiffs' Objections To Report And Recommendation Of Magistrate Judge Granting Apotex Inc.'s Renewed Rule 12(b)(2) Motion To Dismiss For Lack Of Personal Jurisdiction Or In The Alternative To Transfer (D.I. 393) is **OVERRULED**.

2. Aurobindo Pharma Ltd.'s Objection To The Magistrate Judge's Report And Recommendation Regarding Aurobindo Pharma Ltd.'s Motion For Summary Judgment Of No Personal Jurisdiction And For Dismissal For Nonjoinder (D.I. 392) is **OVERRULED**.

3. Aurobindo Pharma USA's Objection To The Magistrate Judge's Report And Recommendation Concerning Aurobindo USA's Motion For Summary Judgment Of Noninfringement And No Subject Matter Jurisdiction (D.I. 391) is **OVERRULED**.

4. The Report And Recommendation Regarding Motions For Summary Judgment And To Dismiss, And Order On Evidentiary Motions (D.I. 389) is **ADOPTED**.

February 19, 2010  
DATE

  
UNITED STATES DISTRICT JUDGE